BGNE - BeiGene Ltd. Company Long-Term Liabilities

Public company logo of BeiGene Ltd. (BGNE)

The visualization of BeiGene, Ltd. (BGNE) market value on the GURU.Markets platform demonstrates the performance of a company competing with pharma behemoths by optimizing its own trials. Meanwhile, current debt stands at 1.66, while profits are constrained by R&D expenditures and the decoupling of ties between the US and China. Business stability relies on a calibrated transportation system for bioactive agents serving global medical programs.

beigene.com (BGNE) Company Long-Term Debt: for the period 07/04/2022 - 10/31/2026

BeOne Medicines (BGNE) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price beigene.com|BGNE - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation BeiGene|BGNE - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share BeiGene|BGNE - Company Book Value|Market Value to Book Value beigene.com|BGNE - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio BeiGene, Ltd.|BGNE - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BeiGene Ltd|BGNE - Company Total Debt|Debts to Book Capitalization BeiGene|BGNE - Company Long-Term Debt|Company Short-Term Loans and Borrowings BeiGene|Immediate Liquidity beigene.com
- earnings and market multiples details:
BGNE - Net Profit
Fundamental company valuation:BGNE (beigene.com)
Brand item of BeiGene, Ltd.

Low debt levels enhance the fundamental stability of BeiGene, Ltd. (BGNE) shares. The size of the business's long-term borrowed capital reflects obligations with maturities exceeding one year, which is critical for financing the large-scale R&D projects of BeiGene, Ltd. (BGNE). This metric measures the company's ability to service loans without compromising operational liquidity. An increase in this indicator may signal a deficiency in equity. An optimal debt balance ensures the development of innovative kinase inhibitors.

Competitors of BeiGene, Ltd. (BGNE)

ONC: Company Long-Term Indebtedness|Halozyme - Company Long-Term Debts|Revolution Medicines Inc (RVMD) - Company Long-Term Liabilities|AAPG: Company Long-Term Debts|Long-Term Debt CG Oncology Therapeutics (CGON)|Company Long-Term Debt UroGen Pharma Ltd.|BCAX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities PSNL (Personalis)|ERAS (Erasca Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts DCTH (Delcath)|YMAB - Company Long-Term Liabilities|AURA: Company Long-Term Liabilities|CADL - Company Long-Term Debts|Accuray (ARAY) - Company Long-Term Debt|SELLAS Life Sciences Group - Company Long-Term Loans and Borrowings|ACTU (Actuate Therapeutics, Inc) - Company Long-Term Debts|Long-Term Debt Citius Oncology Inc CTOR|Company Long-Term Debts HURA|Company Long-Term Debt TARA (protaratx.com)|Company Long-Term Debts FATE (Fate Therapeutics)|Aadi Bioscience, Inc. (WHWK) - Long-Term Debt|TScan - Company Long-Term Debts|Long-Term Debt Volume Champions Oncology CSBR|XBIT: Company Long-Term Debts|Long-Term Indebtedness CEL-SCI CVM|OSTX (OS Therapies) - Company Long-Term Debts|Long-Term Debt Radiopharm Theranostics Ltd RADX|Company Long-Term Debt Artiva Biotherapeutics, Inc. (ARTV)|adlainortye.com - Company Long-Term Indebtedness|Company Long-Term Debts VERU (Veru Inc.)|tempesttx.com (TPST) - Long-Term Debt|XLO: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings RENB (Renovaro Inc.)|muraloncology.com (MURA) - Company Long-Term Debt|KAPA (Kairos Pharma) - Company Long-Term Debt|Company Long-Term Liabilities OKUR|GDTC (CytoMed) - Amount of Long-Term Liabilities|Company Long-Term Debts CRIS|apollomicsinc.com - Company Long-Term Indebtedness|Tharimmune Corp - Company Long-Term Liabilities|Long-Term Debt Volume Advanced Biomed Inc. (ADVB)|Genprex, Inc. - Company Long-Term Debts|CLDI: Company Long-Term Debt|SBFM: Company Long-Term Debts|Long-Term Indebtedness Xenetic Biosciences, Inc. XBIO|Company Long-Term Debt Salarius|Company Long-Term Indebtedness PPBT (Kitov Pharma)|Company Long-Term Debts AONC|CKPT - Long-Term Debt|Company Long-Term Debts ELEV (Elevation Oncology, Inc.)|ICAD - Company Long-Term Liabilities|Ikena - Company Long-Term Debts|NTBL - Company Long-Term Debts|viracta.com (VIRX) - Company Long-Term Debt|Company Long-Term Indebtedness MOR|NAYA (NAYA Biosciences Inc.) - Company Long-Term Debts|Company Long-Term Liabilities Ascentage Pharma Group International (AAPGV)